Introduction
Bone is constantly remodeled by a controlled balance between bone formation by osteoblasts (OBLs) and bone resorption by osteoclasts (OCLs). OBLs are mononucleated bone-forming cells that are derived from mesenchymal stem cells (MSCs) . The differentiation of MSCs into OBLs is regulated by seven important signaling networks (Soltanoff et al., 2009) . Among them, the transforming growth factor-beta (TGF-β)/bone morphogenic protein (BMP) signaling pathway facilitates the activation of two pathways: canonical Smad-dependent pathways and non-canonical Smad-independent signaling pathways, including the p38 mitogen-activated protein kinase pathway (MAPK) (Chen et al., 2012) . Both the Smad and p38 MAPK-dependent pathways result in the activation of Runt-related transcription factor 2 (Runx2), which is a key transcription factor for OBL differentiation (Komori, 2008) . Meanwhile, OCLs are multinucleated bone-resorbing cells that mature from hematopoietic precursors of monocyte/macrophage lineage (Chambers, 2000; Teitelbaum, 2000) . OCL differentiation is regulated by two important factors, macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL). In addition, recent studies have shown that oxidative stress plays important roles in osteoclastogenesis (Lee et al., 2005) .
Liquiritigenin is an aglycone of liquiritin, and it is one of the flavonoids present in Glycyrrhiza radix. Liquiritigenin has been shown to have various pharmacological effects, such as anti-oxidative, anti-tumor, and anti-inflammatory effects (Kupfer et al., 2008 ) (Zhou et al., 2010 Jiang et al., 2013) . Moreover, liquiritigenin has been reported to be a plant-derived, selective estrogen receptor β agonist, indicating that it is probably useful for the treatment of breast cancer and osteoporosis (Mersereau et al., 2008) .
Although several studies have reported the potential utility of liquiritigenin in the treatment of breast cancer, there is little information about the effects of liquiritigenin on osteoporosis. In a previous study, liquiritigenin was shown to exert the following pharmacological effects: increased cell growth, increased alkaline phosphatase activity, promotion of collagen synthesis, and the mineralization of osteoblastic MC3T3-E1 cells (Choi, 2012) . Further, liquiritigenin has been shown to protect MC3T3-E1 cells from oxidative damage induced by pharmacological inhibitors of the mitochondria (Choi et al., 2014) .
Based on these findings, a strong possibility that liquiritigenin has osteogenic activity exists, but such an effect remain to be elucidated. In this study, the effects of liquiritigenin on OBL proliferation and on OCL differentiation were examined.
Materials and methods

Reagents
Liquiritigenin was purchased from Wako Pure Chemicals (Osaka, Japan). M-CSF was purchased from Kyowa Hakko Kogyo (Tokyo, Japan). Recombinant RANKL was prepared as described previously (Hu et al., 2008 Cathepsin K Ab was prepared as described previously (Kamiya et al., 1998) . The Osteo Assay Plate was purchased from Corning (Corning, New York, NY, USA). All other reagents, including phenylmethanesulfonylfluoride (PMSF) and the protease inhibitor cocktail, were obtained from Sigma-Aldrich. Recombinant human bone morphogenetic protein-2 (rhBMP-2) was purchased from R & D systems.
Cell culture
Murine osteoblastic MC3T3-E1 cells (RBRC-RCB1126) were provided by the RIKEN BRC through the National Bio-Resource Project of the MEXT, Japan.
MC3T3-E1 cells were cultured in α-minimal essential medium (α-MEM) (Wako Pure Chemicals, Code: 135-15175; bicarbonate buffered with L-glutamine) containing 10% fetal bovine serum (FBS) with 100 U/mL penicillin and 100 µg/mL streptomycin. When cells were differentiated into OBLs, cells were incubated with α-MEM containing 50 μg/mL ascorbic acid, 5 mM β-glycerolphosphate, and 1 μM dexamethasone, or 100 μM rhBMP-2.
The isolation of bone marrow-derived macrophages (BMMs) was performed as described previously . Briefly, five-week-old male C57BL/6 mice were obtained from CLEA Japan, Inc. (Tokyo, Japan) and handled in our facilities under the approved protocols of the Nagasaki University Animal Care Committee. The BMMs were replated in culture plates and incubated in α-MEM containing 10% FBS with 100 U/mL penicillin and 100 µg/mL streptomycin in the presence of M-CSF (50 ng/mL) and RANKL (50 ng/mL) for 60 h or 72 h, until the cells differentiated into multinucleated mature OCLs.
The cells were fixed with 4% paraformaldehyde and stained for tartrate-resistant acid phosphatase (TRAP) activity using a previously described method (Sakai et al., 2013) . TRAP-positive red-colored cells with 3 or more nuclei were considered mature OCLs. Murine monocytic cell line RAW-D cells were kindly provided by Prof. Toshio Kukita (Kyushu University, Japan) and cultured in α-MEM containing 10% FBS with RANKL (50 ng/mL) (Watanabe et al., 2004) . For bone resorption pit formation, BMMs were seeded onto Osteo Assay Plates coated with thin calcium phosphate films (Corning, New York, NY, USA) and incubated with M-CSF and RANKL for 5 days, until mature OCL resorbed the calcium phosphate film. Cells were dissolved in 5% sodium hypochlorite. Images of the resorption pit were taken with a reverse phase microscope (Olympus, Tokyo, Japan). The ratios of the resorbed areas to the total areas were calculated using Image J image-analysis software (http://rsbweb.nih.gov/ij/) as described previously (Narahara et al., 2012) .
Cell viability assay
Cells seeded in 96-well cell culture plates were incubated with the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) for 1 h, and then the absorbance at 450 nm was measured with a microplate reader (Bio-Rad iMark TM , Hercules, CA, USA).
Western blot analysis
Cells were rinsed twice with ice-cold phosphate-buffered saline (PBS), and lysed in a cell lysis buffer (50 mM Tris-HCl [pH 8.0], 1% Nonidet P-40, 0.5% sodium
Results
Effects of liquiritigenin on the differentiation of osteoblastic MC3T3-E1 cells
Fig . 1A shows the structure of liquiritigenin. We first examined the effects of liquiritigenin on the differentiation of osteoblastic MC3T3-E1 cells under two different induced conditions. Firstly, upon stimulation of MC3T3-E1 cells with β-glycerophosphate, ascorbic acid, and dexamethasone, alkaline phosphatase staining analysis showed that liquiritigenin dose-dependently promoted the differentiation of osteoblastic MC3T3-E1 cells (Fig. 1B) . Secondly, in MC3T3-E1 cells stimulated with BMP-2, alkaline phosphatase staining also showed that liquiritigenin dose-dependently increased osteoblast differentiation (Fig. 1C) . These results confirm that liquiritigenin promotes OBL differentiation of MC3T3-E1 cells.
Effects of liquiritigenin on the intracellular signaling mediating the differentiation of osteoblastic MC3T3-E1 cells
Next, the effects of liquiritigenin on the intracellular signaling mediating the differentiation of MC3T3-E1 cells induced by BMP-2 were investigated (Fig. 1D) 
Liquiritigenin inhibits osteoclastogenesis in vitro
To evaluate the effects of liquiritigenin on RANKL-induced osteoclastogenesis, the effects of liquiritigenin on OCL differentiation of RAW-D cells with RANKL (50 ng/mL) were investigated by TRAP staining, which is a standard method to test OCL formation. Liquiritigenin inhibited the formation of mononuclear and multinuclear
OCLs derived from RAW-D cells (Fig 2A) . The number of TRAP-positive, multinucleated OCLs after liquiritigenin treatment decreased in a dose-dependent indistinguishable from that of untreated cells, although the viability of cells treated with deltamethrin at 50 µM or 100 µM significantly decreased (Fig. 2C ).
To examine further whether similar results could also be observed in native cells, the effects of liquiritigenin on RANKL-induced osteoclastogenesis in BMMs were tested.
The TRAP staining indicated that 10 and 50 µM liquiritigenin treatment decreased multinucleated OCL formation (Fig 2D) . The number of TRAP-positive BMM-derived
OCLs significantly decreased after liquiritigenin treatment (Fig. 2E) . The viability of
OCLs treated with 2 -10 µM liquiritigenin was comparable to that of untreated cells;
however, 50 -100 µM liquiritigenin treatment slightly increased cell viability (Fig. 2F ).
These results indicate that liquiritigenin significantly inhibits the osteoclastogenesis of RAW-D cells and BMMs, although liquiritigenin shows different effects on cell viability in RAW-D cells and BMMs.
Effects of liquiritigenin on the bone-resorption activity of OCLs
To determine whether liquiritigenin decreases the bone-resorption activity of OCLs, a pit formation assay with BMM-derived OCLs was performed. Bone resorption activity under two different conditions was tested. In the first condition, liquiritigenin was added at the beginning of stimulation with RANKL (50 ng/mL) and M-CSF (30 ng/mL) (Fig. 3A, showing a) . In the second condition, liquiritigenin was added three days after activation, when BMMs were differentiated into active OCLs (Fig. 3A, showing b).
In order to compare the resorption pit area, when untreated OCLs had moderate resorbing activity, the OCLs treated with liquiritigenin at the beginning exhibited reduced resorbing activity (Fig. 3B) . Moreover, the OCLs treated with liquiritigenin after OCL activation also showed a reduced bone-resorption activity (Fig. 3C) . These results indicate that liquiritigenin impairs the bone-resorption activity of OCLs.
Effects of liquiritigenin on the expression levels of OCL marker proteins and intracellular signaling
To examine the effects of liquiritigenin on OCLs, the expression levels of OCL marker proteins by western blotting were determined. As shown in Fig. 4A , although the expression levels of c-fms, c-fos, and RANK were unchanged at lower concentrations (up to 10 µM) of liquiritigenin, they decreased at higher concentrations (50 -100 µM) of liquiritigenin. However, the protein levels of NFATc1 considerably decreased upon 10 µM liquiritigenin treatment. Consistent with these results, the expression levels of Src and cathepsin K, which are transcriptionally regulated by NFATc1, were also found to be decreased by liquiritigenin treatment. Thus, liquiritigenin inhibits the expression of various OCL marker proteins.
Therefore, the expression levels of HO-1, a phase II antioxidant cytoprotective enzyme against oxidative stress, were examined after liquiritigenin treatment. HO-1 levels increased upon 50 or 100 µM liquiritigenin treatment, indicating that liquiritigenin induced a weak expression of HO-1 in OCLs (Fig. 4A) .
Finally, the effects of liquiritigenin on RANKL-induced early intracellular signaling pathways, including the phosphorylation of p38 MAPK, JNK, IκBα, Erk, and Akt were analyzed by western blotting, during the OCL differentiation of BMMs, since these signaling cascades are important for osteoclastogenesis (Boyle et al., 2003) . BMMs were pre-incubated with 50 μM liquiritigenin for 24 h and subsequently stimulated with RANKL according to a previous protocol (Lee et al., 2010) . Liquiritigenin slightly inhibited the phosphorylation of Erk, JNK, and IκBα (Fig. 4B) . However, the phosphorylation of p38 and Akt was enhanced after liquiritigenin. These results indicate that liquiritigenin inhibits some RANKL-induced signaling cascades such as Erk, JNK, and IκBα, but conversely increases p38 and Akt signaling.
Discussion
A previous study has reported that liquiritigenin induced enhanced cell growth, increased alkaline phosphatase activity, increased collagen synthesis, and the mineralization of osteoblastic MC3T3-E1 cells (Choi, 2012) . However, the detailed The effects of liquiritigenin on cell viability are most likely to be rather mild. The previous study reported that liquiritigenin increased cell growth, alkaline phosphatase activity, and collagen synthesis in osteoblastic MC3T3-E1 cells (Choi, 2012) .
Consistent with these results, this study also showed that liquiritigenin increased cell growth and alkaline phosphatase activity. Moreover, liquiritigenin caused significantly In addition to cell viability, liquiritigenin has been shown to significantly decrease the production of OCL differentiation factors, such as tumor necrosis factor-α, interleukin-6, and receptor RANKL in osteoblastic MC3T3-E1 cells (Choi, 2012) .
Moreover, this study showed that liquiritigenin prevented the OCL differentiation and bone-resorption activity of OCLs (Choi, 2012) . Thus, liquiritigenin has effects on decreasing bone resorption.
Estrogen receptors are speculated to be target molecules of liquiritigenin in bone cells. Since liquiritigenin has been shown to selectively bind to estrogen receptor β, it is most likely that liquiritigenin works as a kind of "phytoestrogen" (Mersereau et al., 2008) . Phytoestrogens are plant-derived bioactive compounds that have structural and physiological effects similar to that of estradiol. Estrogen receptor α regulates the proliferative effects of estrogens in the target tissues, whereas estrogen receptor β has rather suppressive effects on estrogen receptor α (Jiang et al., 2013) . Generally, phytoestrogens have dual effects on bone cells, such as the promotion of OBL maturation and the inhibition of OCL differentiation. For example, genistein, a representative soy isoflavone, has been shown to have effects on the enhancement of OBL differentiation (Chen et al., 2003) and the inhibition of OCL differentiation (Bitto et al., 2010) . Since genistein prevents trabecular bone loss in ovariectomy mouse in vivo, which is a model of osteoporosis (Wu et al., 2001) , determining whether liquiritigenin can promote bone formation in vivo is of interest.
During preparation of this study, Chen et al. have reported that several dietary phenolic acids stimulate OBL differentiation and proliferation, and it inhibits adipocyte differentiation in vitro, leading to increased bone mass in vivo (Chen et al., 2014) .
Considering these similarities, it will be of interest to determine whether liquiritigenin has inhibitory effects on adipocyte differentiation in vitro, resulting in increased bone mass in vivo.
Conclusions
This study determined that liquiritigenin promotes OBL differentiation of 
